Brief: Onxeo Presents Positive AsiDNA Preclinical Study Results

Valerio Therapeutics SA

15/03/2018 06:19

March 15 (Reuters) - ONXEO SA  C4X.PA :
    * ANNOUNCES PRESENTATION OF TWO PRECLINICAL STUDY ABSTRACTS
HIGHLIGHTING ASIDNA
    * WE BELIEVE ASIDNA HOLDS SIGNIFICANT PROMISE AS TREATMENT
FOR
SOLID TUMORS - CHIEF SCIENTIFIC OFFICER
    * ON ASIDNA AND HDAC INHIBITORS: RESULTS DEMONSTRATED THAT
BELINOSTAT TREATMENT INDUCES DNA BREAK ACCUMULATION
    * ON ASIDNA AND HDAC INHIBITORS: RESULTS DEMONSTRATED THAT
BELINOSTAT TREATMENT INDUCES GENETIC INSTABILITY IN TUMOR CELLS
    * ASIDNA INDUCED HIGH POTENTIATION OF BELINOSTAT ACTIVITY ON
ITS
TARGETS
    * RESULTS SUPPORT RATIONALE TO INVESTIGATE IN-VIVO ACTIVITY
OF
THIS COMBINATION IN DIFFERENT TUMOR TYPES

Source text for Eikon:  ID:nNDL5QMQqP 
Further company coverage:  C4X.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))